Global Haemophilus b Conjugate Vaccine (Hib) Market Insights and Forecast to 2031

Report ID: 1669357 | Published Date: Jan 2025 | No. of Page: 79 | Base Year: 2024 | Rating: 4.5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Haemophilus b Conjugate Vaccine (Hib) Product Introduction
    1.2 Market by Type
        1.2.1 Global Haemophilus b Conjugate Vaccine (Hib) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Inactivated Vaccine
        1.2.3 Live Attenuated Vaccine
    1.3 Market by Application
        1.3.1 Global Haemophilus b Conjugate Vaccine (Hib) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Government Institution
        1.3.3 Private Sector
        1.3.4 Other
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales Estimates and Forecasts 2017-2028
    2.2 Global Haemophilus b Conjugate Vaccine (Hib) Revenue Estimates and Forecasts 2017-2028
    2.3 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region
        2.4.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region (2017-2022)
        2.4.2 Global Sales Haemophilus b Conjugate Vaccine (Hib) by Region (2023-2028)
    2.5 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Region
        2.5.1 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Region (2017-2022)
        2.5.2 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Manufacturers
        3.1.1 Global Top Haemophilus b Conjugate Vaccine (Hib) Manufacturers by Sales (2017-2022)
        3.1.2 Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Haemophilus b Conjugate Vaccine (Hib) in 2021
    3.2 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Manufacturers
        3.2.1 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Manufacturers (2017-2022)
        3.2.2 Global Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Haemophilus b Conjugate Vaccine (Hib) Revenue in 2021
    3.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Haemophilus b Conjugate Vaccine (Hib) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Haemophilus b Conjugate Vaccine (Hib) Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Type
        4.1.1 Global Haemophilus b Conjugate Vaccine (Hib) Historical Sales by Type (2017-2022)
        4.1.2 Global Haemophilus b Conjugate Vaccine (Hib) Forecasted Sales by Type (2023-2028)
        4.1.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Type (2017-2028)
    4.2 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Type
        4.2.1 Global Haemophilus b Conjugate Vaccine (Hib) Historical Revenue by Type (2017-2022)
        4.2.2 Global Haemophilus b Conjugate Vaccine (Hib) Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Type (2017-2028)
    4.3 Global Haemophilus b Conjugate Vaccine (Hib) Price by Type
        4.3.1 Global Haemophilus b Conjugate Vaccine (Hib) Price by Type (2017-2022)
        4.3.2 Global Haemophilus b Conjugate Vaccine (Hib) Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Haemophilus b Conjugate Vaccine (Hib) Sales by Application
        5.1.1 Global Haemophilus b Conjugate Vaccine (Hib) Historical Sales by Application (2017-2022)
        5.1.2 Global Haemophilus b Conjugate Vaccine (Hib) Forecasted Sales by Application (2023-2028)
        5.1.3 Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Application (2017-2028)
    5.2 Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Application
        5.2.1 Global Haemophilus b Conjugate Vaccine (Hib) Historical Revenue by Application (2017-2022)
        5.2.2 Global Haemophilus b Conjugate Vaccine (Hib) Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Application (2017-2028)
    5.3 Global Haemophilus b Conjugate Vaccine (Hib) Price by Application
        5.3.1 Global Haemophilus b Conjugate Vaccine (Hib) Price by Application (2017-2022)
        5.3.2 Global Haemophilus b Conjugate Vaccine (Hib) Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Haemophilus b Conjugate Vaccine (Hib) Market Size by Type
        6.1.1 North America Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2017-2028)
        6.1.2 North America Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2017-2028)
    6.2 North America Haemophilus b Conjugate Vaccine (Hib) Market Size by Application
        6.2.1 North America Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2017-2028)
        6.2.2 North America Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2017-2028)
    6.3 North America Haemophilus b Conjugate Vaccine (Hib) Market Size by Country
        6.3.1 North America Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2017-2028)
        6.3.2 North America Haemophilus b Conjugate Vaccine (Hib) Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Haemophilus b Conjugate Vaccine (Hib) Market Size by Type
        7.1.1 Europe Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2017-2028)
        7.1.2 Europe Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2017-2028)
    7.2 Europe Haemophilus b Conjugate Vaccine (Hib) Market Size by Application
        7.2.1 Europe Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2017-2028)
        7.2.2 Europe Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2017-2028)
    7.3 Europe Haemophilus b Conjugate Vaccine (Hib) Market Size by Country
        7.3.1 Europe Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2017-2028)
        7.3.2 Europe Haemophilus b Conjugate Vaccine (Hib) Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Market Size by Type
        8.1.1 Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2017-2028)
        8.1.2 Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2017-2028)
    8.2 Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Market Size by Application
        8.2.1 Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2017-2028)
        8.2.2 Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2017-2028)
    8.3 Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Market Size by Region
        8.3.1 Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Sales by Region (2017-2028)
        8.3.2 Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Haemophilus b Conjugate Vaccine (Hib) Market Size by Type
        9.1.1 Latin America Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2017-2028)
        9.1.2 Latin America Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2017-2028)
    9.2 Latin America Haemophilus b Conjugate Vaccine (Hib) Market Size by Application
        9.2.1 Latin America Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2017-2028)
        9.2.2 Latin America Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2017-2028)
    9.3 Latin America Haemophilus b Conjugate Vaccine (Hib) Market Size by Country
        9.3.1 Latin America Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2017-2028)
        9.3.2 Latin America Haemophilus b Conjugate Vaccine (Hib) Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Market Size by Type
        10.1.1 Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2017-2028)
    10.2 Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Market Size by Application
        10.2.1 Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2017-2028)
    10.3 Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Market Size by Country
        10.3.1 Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Sanofi Pasteur, SA
        11.1.1 Sanofi Pasteur, SA Corporation Information
        11.1.2 Sanofi Pasteur, SA Overview
        11.1.3 Sanofi Pasteur, SA Haemophilus b Conjugate Vaccine (Hib) Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Sanofi Pasteur, SA Haemophilus b Conjugate Vaccine (Hib) Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Sanofi Pasteur, SA Recent Developments
    11.2 GSK
        11.2.1 GSK Corporation Information
        11.2.2 GSK Overview
        11.2.3 GSK Haemophilus b Conjugate Vaccine (Hib) Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 GSK Haemophilus b Conjugate Vaccine (Hib) Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 GSK Recent Developments
    11.3 Merck
        11.3.1 Merck Corporation Information
        11.3.2 Merck Overview
        11.3.3 Merck Haemophilus b Conjugate Vaccine (Hib) Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Merck Haemophilus b Conjugate Vaccine (Hib) Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Merck Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Haemophilus b Conjugate Vaccine (Hib) Industry Chain Analysis
    12.2 Haemophilus b Conjugate Vaccine (Hib) Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Haemophilus b Conjugate Vaccine (Hib) Production Mode & Process
    12.4 Haemophilus b Conjugate Vaccine (Hib) Sales and Marketing
        12.4.1 Haemophilus b Conjugate Vaccine (Hib) Sales Channels
        12.4.2 Haemophilus b Conjugate Vaccine (Hib) Distributors
    12.5 Haemophilus b Conjugate Vaccine (Hib) Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Haemophilus b Conjugate Vaccine (Hib) Industry Trends
    13.2 Haemophilus b Conjugate Vaccine (Hib) Market Drivers
    13.3 Haemophilus b Conjugate Vaccine (Hib) Market Challenges
    13.4 Haemophilus b Conjugate Vaccine (Hib) Market Restraints
14 Key Findings in The Global Haemophilus b Conjugate Vaccine (Hib) Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer

List of Tables
    Table 1. Global Haemophilus b Conjugate Vaccine (Hib) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Inactivated Vaccine
    Table 3. Major Manufacturers of Live Attenuated Vaccine
    Table 4. Global Haemophilus b Conjugate Vaccine (Hib) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 5. Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 6. Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region (2017-2022) & (K Doses)
    Table 7. Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Region (2017-2022)
    Table 8. Global Haemophilus b Conjugate Vaccine (Hib) Sales by Region (2023-2028) & (K Doses)
    Table 9. Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Region (2023-2028)
    Table 10. Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Region (2017-2022) & (US$ Million)
    Table 11. Global Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Region (2017-2022)
    Table 12. Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Region (2023-2028) & (US$ Million)
    Table 13. Global Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Region (2023-2028)
    Table 14. Global Haemophilus b Conjugate Vaccine (Hib) Sales by Manufacturers (2017-2022) & (K Doses)
    Table 15. Global Haemophilus b Conjugate Vaccine (Hib) Sales Share by Manufacturers (2017-2022)
    Table 16. Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 17. Global Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Manufacturers (2017-2022)
    Table 18. Haemophilus b Conjugate Vaccine (Hib) Price by Manufacturers (2017-2022) &(US$/Dose)
    Table 19. Global Haemophilus b Conjugate Vaccine (Hib) Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 20. Global Haemophilus b Conjugate Vaccine (Hib) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Haemophilus b Conjugate Vaccine (Hib) as of 2021)
    Table 21. Haemophilus b Conjugate Vaccine (Hib) Manufacturing Base Distribution and Headquarters
    Table 22. Manufacturers Haemophilus b Conjugate Vaccine (Hib) Product Offered
    Table 23. Date of Manufacturers Enter into Haemophilus b Conjugate Vaccine (Hib) Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2017-2022) & (K Doses)
    Table 26. Global Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2023-2028) & (K Doses)
    Table 27. Global Haemophilus b Conjugate Vaccine (Hib) Sales Share by Type (2017-2022)
    Table 28. Global Haemophilus b Conjugate Vaccine (Hib) Sales Share by Type (2023-2028)
    Table 29. Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2017-2022) & (US$ Million)
    Table 30. Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2023-2028) & (US$ Million)
    Table 31. Global Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Type (2017-2022)
    Table 32. Global Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Type (2023-2028)
    Table 33. Haemophilus b Conjugate Vaccine (Hib) Price by Type (2017-2022) & (US$/Dose)
    Table 34. Global Haemophilus b Conjugate Vaccine (Hib) Price Forecast by Type (2023-2028) & (US$/Dose)
    Table 35. Global Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2017-2022) & (K Doses)
    Table 36. Global Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2023-2028) & (K Doses)
    Table 37. Global Haemophilus b Conjugate Vaccine (Hib) Sales Share by Application (2017-2022)
    Table 38. Global Haemophilus b Conjugate Vaccine (Hib) Sales Share by Application (2023-2028)
    Table 39. Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2017-2022) & (US$ Million)
    Table 40. Global Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2023-2028) & (US$ Million)
    Table 41. Global Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Application (2017-2022)
    Table 42. Global Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Application (2023-2028)
    Table 43. Haemophilus b Conjugate Vaccine (Hib) Price by Application (2017-2022) & (US$/Dose)
    Table 44. Global Haemophilus b Conjugate Vaccine (Hib) Price Forecast by Application (2023-2028) & (US$/Dose)
    Table 45. North America Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2017-2022) & (K Doses)
    Table 46. North America Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2023-2028) & (K Doses)
    Table 47. North America Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2017-2022) & (US$ Million)
    Table 48. North America Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2023-2028) & (US$ Million)
    Table 49. North America Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2017-2022) & (K Doses)
    Table 50. North America Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2023-2028) & (K Doses)
    Table 51. North America Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2017-2022) & (US$ Million)
    Table 52. North America Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2023-2028) & (US$ Million)
    Table 53. North America Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2017-2022) & (K Doses)
    Table 54. North America Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2023-2028) & (K Doses)
    Table 55. North America Haemophilus b Conjugate Vaccine (Hib) Revenue by Country (2017-2022) & (US$ Million)
    Table 56. North America Haemophilus b Conjugate Vaccine (Hib) Revenue by Country (2023-2028) & (US$ Million)
    Table 57. Europe Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2017-2022) & (K Doses)
    Table 58. Europe Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2023-2028) & (K Doses)
    Table 59. Europe Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2017-2022) & (US$ Million)
    Table 60. Europe Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2023-2028) & (US$ Million)
    Table 61. Europe Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2017-2022) & (K Doses)
    Table 62. Europe Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2023-2028) & (K Doses)
    Table 63. Europe Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2017-2022) & (US$ Million)
    Table 64. Europe Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2023-2028) & (US$ Million)
    Table 65. Europe Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2017-2022) & (K Doses)
    Table 66. Europe Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2023-2028) & (K Doses)
    Table 67. Europe Haemophilus b Conjugate Vaccine (Hib) Revenue by Country (2017-2022) & (US$ Million)
    Table 68. Europe Haemophilus b Conjugate Vaccine (Hib) Revenue by Country (2023-2028) & (US$ Million)
    Table 69. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2017-2022) & (K Doses)
    Table 70. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2023-2028) & (K Doses)
    Table 71. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2017-2022) & (US$ Million)
    Table 72. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2023-2028) & (US$ Million)
    Table 73. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2017-2022) & (K Doses)
    Table 74. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2023-2028) & (K Doses)
    Table 75. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2017-2022) & (US$ Million)
    Table 76. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2023-2028) & (US$ Million)
    Table 77. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Sales by Region (2017-2022) & (K Doses)
    Table 78. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Sales by Region (2023-2028) & (K Doses)
    Table 79. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue by Region (2017-2022) & (US$ Million)
    Table 80. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue by Region (2023-2028) & (US$ Million)
    Table 81. Latin America Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2017-2022) & (K Doses)
    Table 82. Latin America Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2023-2028) & (K Doses)
    Table 83. Latin America Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2017-2022) & (US$ Million)
    Table 84. Latin America Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2023-2028) & (US$ Million)
    Table 85. Latin America Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2017-2022) & (K Doses)
    Table 86. Latin America Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2023-2028) & (K Doses)
    Table 87. Latin America Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2017-2022) & (US$ Million)
    Table 88. Latin America Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2023-2028) & (US$ Million)
    Table 89. Latin America Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2017-2022) & (K Doses)
    Table 90. Latin America Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2023-2028) & (K Doses)
    Table 91. Latin America Haemophilus b Conjugate Vaccine (Hib) Revenue by Country (2017-2022) & (US$ Million)
    Table 92. Latin America Haemophilus b Conjugate Vaccine (Hib) Revenue by Country (2023-2028) & (US$ Million)
    Table 93. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2017-2022) & (K Doses)
    Table 94. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Sales by Type (2023-2028) & (K Doses)
    Table 95. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2017-2022) & (US$ Million)
    Table 96. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Revenue by Type (2023-2028) & (US$ Million)
    Table 97. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2017-2022) & (K Doses)
    Table 98. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Sales by Application (2023-2028) & (K Doses)
    Table 99. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2017-2022) & (US$ Million)
    Table 100. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Revenue by Application (2023-2028) & (US$ Million)
    Table 101. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2017-2022) & (K Doses)
    Table 102. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Sales by Country (2023-2028) & (K Doses)
    Table 103. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Revenue by Country (2017-2022) & (US$ Million)
    Table 104. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Revenue by Country (2023-2028) & (US$ Million)
    Table 105. Sanofi Pasteur, SA Corporation Information
    Table 106. Sanofi Pasteur, SA Description and Major Businesses
    Table 107. Sanofi Pasteur, SA Haemophilus b Conjugate Vaccine (Hib) Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2017-2022)
    Table 108. Sanofi Pasteur, SA Haemophilus b Conjugate Vaccine (Hib) Product Model Numbers, Pictures, Descriptions and Specifications
    Table 109. Sanofi Pasteur, SA Recent Developments
    Table 110. GSK Corporation Information
    Table 111. GSK Description and Major Businesses
    Table 112. GSK Haemophilus b Conjugate Vaccine (Hib) Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2017-2022)
    Table 113. GSK Haemophilus b Conjugate Vaccine (Hib) Product Model Numbers, Pictures, Descriptions and Specifications
    Table 114. GSK Recent Developments
    Table 115. Merck Corporation Information
    Table 116. Merck Description and Major Businesses
    Table 117. Merck Haemophilus b Conjugate Vaccine (Hib) Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2017-2022)
    Table 118. Merck Haemophilus b Conjugate Vaccine (Hib) Product Model Numbers, Pictures, Descriptions and Specifications
    Table 119. Merck Recent Developments
    Table 120. Key Raw Materials Lists
    Table 121. Raw Materials Key Suppliers Lists
    Table 122. Haemophilus b Conjugate Vaccine (Hib) Distributors List
    Table 123. Haemophilus b Conjugate Vaccine (Hib) Customers List
    Table 124. Haemophilus b Conjugate Vaccine (Hib) Market Trends
    Table 125. Haemophilus b Conjugate Vaccine (Hib) Market Drivers
    Table 126. Haemophilus b Conjugate Vaccine (Hib) Market Challenges
    Table 127. Haemophilus b Conjugate Vaccine (Hib) Market Restraints
    Table 128. Research Programs/Design for This Report
    Table 129. Key Data Information from Secondary Sources
    Table 130. Key Data Information from Primary Sources
List of Figures
    Figure 1. Haemophilus b Conjugate Vaccine (Hib) Product Picture
    Figure 3. Global Haemophilus b Conjugate Vaccine (Hib) Market Share by Type in 2021 & 2028
    Figure 3. Inactivated Vaccine Product Picture
    Figure 4. Live Attenuated Vaccine Product Picture
    Figure 5. Global Haemophilus b Conjugate Vaccine (Hib) Market Share by Application in 2021 & 2028
    Figure 6. Government Institution
    Figure 7. Private Sector
    Figure 8. Other
    Figure 9. Haemophilus b Conjugate Vaccine (Hib) Report Years Considered
    Figure 10. Global Haemophilus b Conjugate Vaccine (Hib) Sales 2017-2028 (K Doses)
    Figure 11. Global Haemophilus b Conjugate Vaccine (Hib) Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Haemophilus b Conjugate Vaccine (Hib) Revenue 2017-2028 (US$ Million)
    Figure 13. Global Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 14. Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Region (2017-2022)
    Figure 15. Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Region (2023-2028)
    Figure 16. North America Haemophilus b Conjugate Vaccine (Hib) Sales YoY (2017-2028) & (K Doses)
    Figure 17. North America Haemophilus b Conjugate Vaccine (Hib) Revenue YoY (2017-2028) & (US$ Million)
    Figure 18. Europe Haemophilus b Conjugate Vaccine (Hib) Sales YoY (2017-2028) & (K Doses)
    Figure 19. Europe Haemophilus b Conjugate Vaccine (Hib) Revenue YoY (2017-2028) & (US$ Million)
    Figure 20. Asia-Pacific Haemophilus b Conjugate Vaccine (Hib) Sales YoY (2017-2028) & (K Doses)
    Figure 21. Asia-Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Latin America Haemophilus b Conjugate Vaccine (Hib) Sales YoY (2017-2028) & (K Doses)
    Figure 23. Latin America Haemophilus b Conjugate Vaccine (Hib) Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Middle East & Africa Haemophilus b Conjugate Vaccine (Hib) Sales YoY (2017-2028) & (K Doses)
    Figure 25. Middle East & Africa Haemophilus b Conjugate Vaccine (Hib) Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. The Haemophilus b Conjugate Vaccine (Hib) Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 27. The Top 5 and 10 Largest Manufacturers of Haemophilus b Conjugate Vaccine (Hib) in the World: Market Share by Haemophilus b Conjugate Vaccine (Hib) Revenue in 2021
    Figure 28. Global Haemophilus b Conjugate Vaccine (Hib) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 29. Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Type (2017-2028)
    Figure 30. Global Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Type (2017-2028)
    Figure 31. Global Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Application (2017-2028)
    Figure 32. Global Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Application (2017-2028)
    Figure 33. North America Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Type (2017-2028)
    Figure 34. North America Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Type (2017-2028)
    Figure 35. North America Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Application (2017-2028)
    Figure 36. North America Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Application (2017-2028)
    Figure 37. North America Haemophilus b Conjugate Vaccine (Hib) Sales Share by Country (2017-2028)
    Figure 38. North America Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Country (2017-2028)
    Figure 39. U.S. Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 40. Canada Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 41. Europe Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Type (2017-2028)
    Figure 42. Europe Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Type (2017-2028)
    Figure 43. Europe Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Application (2017-2028)
    Figure 44. Europe Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Application (2017-2028)
    Figure 45. Europe Haemophilus b Conjugate Vaccine (Hib) Sales Share by Country (2017-2028)
    Figure 46. Europe Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Country (2017-2028)
    Figure 47. Germany Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 48. France Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 49. U.K. Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 50. Italy Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 51. Russia Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 52. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Type (2017-2028)
    Figure 53. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Type (2017-2028)
    Figure 54. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Application (2017-2028)
    Figure 55. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Application (2017-2028)
    Figure 56. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Sales Share by Region (2017-2028)
    Figure 57. Asia Pacific Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Region (2017-2028)
    Figure 58. China Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 59. Japan Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 60. South Korea Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 61. India Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 62. Australia Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 63. Taiwan Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 64. Indonesia Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 65. Thailand Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 66. Malaysia Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 67. Philippines Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 68. Latin America Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Type (2017-2028)
    Figure 69. Latin America Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Type (2017-2028)
    Figure 70. Latin America Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Application (2017-2028)
    Figure 71. Latin America Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Application (2017-2028)
    Figure 72. Latin America Haemophilus b Conjugate Vaccine (Hib) Sales Share by Country (2017-2028)
    Figure 73. Latin America Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Country (2017-2028)
    Figure 74. Mexico Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 75. Brazil Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 76. Argentina Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 77. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Type (2017-2028)
    Figure 78. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Type (2017-2028)
    Figure 79. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Sales Market Share by Application (2017-2028)
    Figure 80. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Revenue Market Share by Application (2017-2028)
    Figure 81. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Sales Share by Country (2017-2028)
    Figure 82. Middle East and Africa Haemophilus b Conjugate Vaccine (Hib) Revenue Share by Country (2017-2028)
    Figure 83. Turkey Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 84. Saudi Arabia Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 85. UAE Haemophilus b Conjugate Vaccine (Hib) Revenue (2017-2028) & (US$ Million)
    Figure 86. Haemophilus b Conjugate Vaccine (Hib) Value Chain
    Figure 87. Haemophilus b Conjugate Vaccine (Hib) Production Process
    Figure 88. Channels of Distribution
    Figure 89. Distributors Profiles
    Figure 90. Bottom-up and Top-down Approaches for This Report
    Figure 91. Data Triangulation
    Figure 92. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Sanofi Pasteur, SA
GSK
Merck
Frequently Asked Questions
Haemophilus b Conjugate Vaccine (Hib) report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Haemophilus b Conjugate Vaccine (Hib) report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Haemophilus b Conjugate Vaccine (Hib) report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

DTaP Vaccine

DTaP Vaccine market is segmented by Type and by Application. Players, stakeholders, and other par ... Read More